Objective:

To evaluate the effectiveness of blood-based biomarkers in monitoring treatment response and detecting recurrence in HPV-associated head and neck cancer.

Approach:

Key Findings:

• Both assays demonstrated 100% detection prior to treatment.
• An overall percent agreement of 91% was observed across 85 longitudinal samples.
• ctHPV DNA was consistently detected at higher absolute levels compared to ctDNA.
• In cases where ctHPV DNA was positive but ctDNA was negative, this occurred during neoadjuvant treatment monitoring.

Interpretation:

Conclusion:

Ongoing analyses will define how these tools can be optimally integrated into response assessment, treatment adaptation, and surveillance strategies.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.